This old version of Proteopedia is provided for student assignments while the new version is undergoing repairs. Content and edits done in this old version of Proteopedia after March 1, 2026 will eventually be lost when it is retired in about June of 2026.
Apply for new accounts at the new Proteopedia. Your logins will work in both the old and new versions.
3rov
From Proteopedia
| Line 1: | Line 1: | ||
==Insulin's biosynthesis and activity have opposing structural requirements: a new factor in neonatal diabetes mellitus== | ==Insulin's biosynthesis and activity have opposing structural requirements: a new factor in neonatal diabetes mellitus== | ||
| - | <StructureSection load='3rov' size='340' side='right' caption='[[3rov]], [[Resolution|resolution]] 2.30Å' scene=''> | + | <StructureSection load='3rov' size='340' side='right'caption='[[3rov]], [[Resolution|resolution]] 2.30Å' scene=''> |
== Structural highlights == | == Structural highlights == | ||
<table><tr><td colspan='2'>[[3rov]] is a 12 chain structure. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=3ROV OCA]. For a <b>guided tour on the structure components</b> use [http://oca.weizmann.ac.il/oca-docs/fgij/fg.htm?mol=3ROV FirstGlance]. <br> | <table><tr><td colspan='2'>[[3rov]] is a 12 chain structure. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=3ROV OCA]. For a <b>guided tour on the structure components</b> use [http://oca.weizmann.ac.il/oca-docs/fgij/fg.htm?mol=3ROV FirstGlance]. <br> | ||
| Line 13: | Line 13: | ||
== Function == | == Function == | ||
[[http://www.uniprot.org/uniprot/INS_HUMAN INS_HUMAN]] Insulin decreases blood glucose concentration. It increases cell permeability to monosaccharides, amino acids and fatty acids. It accelerates glycolysis, the pentose phosphate cycle, and glycogen synthesis in liver. | [[http://www.uniprot.org/uniprot/INS_HUMAN INS_HUMAN]] Insulin decreases blood glucose concentration. It increases cell permeability to monosaccharides, amino acids and fatty acids. It accelerates glycolysis, the pentose phosphate cycle, and glycogen synthesis in liver. | ||
| + | |||
| + | ==See Also== | ||
| + | *[[Insulin 3D Structures|Insulin 3D Structures]] | ||
== References == | == References == | ||
<references/> | <references/> | ||
__TOC__ | __TOC__ | ||
</StructureSection> | </StructureSection> | ||
| + | [[Category: Large Structures]] | ||
[[Category: Arvan, P]] | [[Category: Arvan, P]] | ||
[[Category: Brange, J]] | [[Category: Brange, J]] | ||
Revision as of 18:11, 14 August 2019
Insulin's biosynthesis and activity have opposing structural requirements: a new factor in neonatal diabetes mellitus
| |||||||||||
Categories: Large Structures | Arvan, P | Brange, J | Dodson, E J | Dodson, G G | Hu, S Q | Hua, Q X | Huang, K | Jia, W H | Katsoyannis, P G | Liu, M | Nakagawa, S H | Turkenburg, M | Wan, Z L | Wang, S H | Weiss, M A | Whittaker, J | Whittingham, J | Xu, B | Global health | Hormone | Insulin fibrillation | Long-acting insulin analog | Receptor binding protein engineering | Stabilizing | Zinc-binding site
